Core Insights - The company, Weili Zhibo, focuses on three core technology platforms targeting tumors and autoimmune diseases, including LeadsBody, X-body, and TOPiKinetics [1] - LBL-024 has a broad indication layout with 12 indications and 9 ongoing clinical trials, including a pivotal study expected to submit a BLA by Q3 2026 [1] - LBL-034 is currently in a Phase II study with promising safety and efficacy data across four patient populations, including those with relapsed refractory multiple myeloma [2] Company Developments - The company has established seamless capabilities in early research, translational medicine, clinical development, CMC, and business expansion [1] - Two autoimmune disease products have achieved overseas collaboration, with LBL-047 having enrolled its first patient and LBL-051 planning to submit a clinical application to the FDA in Q1 2026 [2] Financial Projections - Revenue forecasts for 2025-2027 are estimated at 175.0 million, 196.0 million, and 200.8 million, reflecting year-on-year growth of -/12.0%/+2.4% [2] - The current stock price corresponds to PS ratios of 62, 55, and 54 for the respective years [2] - The company is expected to experience significant clinical data catalysts in 2026, with a potential commercialization inflection point in 2027 [2]
维立志博-B(9887.HK)：三大技术平台IO2.0+TCE+ADC 聚焦肿瘤和自免首次覆盖